Certara, Inc. (CERT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Certara, Inc. (CERT) Healthcare & Pipeline Overview

Certara, Inc. delivers biosimulation software and technology-enabled services, optimizing drug discovery, preclinical, and clinical research. Serving biopharmaceutical companies and academic institutions globally, Certara streamlines regulatory submissions and enhances market access, leveraging a comprehensive suite of software and services for improved drug development outcomes.

What Is the Investment Thesis for CERT?

Certara operates in the growing biosimulation market, driven by increasing R&D spending in the pharmaceutical industry and the need for more efficient drug development processes. The company's comprehensive software and service offerings position it as a key partner for biopharmaceutical companies seeking to optimize their drug development pipelines. A key value driver is Certara's ability to help clients reduce development costs and timelines, which can translate into significant savings and faster market entry. The company's gross margin of 61.5% indicates a strong pricing power and efficient cost management. Ongoing catalysts include increasing adoption of biosimulation in regulatory submissions and expanding applications of biosimulation in personalized medicine. Potential risks include competition from other biosimulation providers and the complexity of integrating biosimulation into existing drug development workflows.

Based on FMP financials and quantitative analysis

CERT Key Highlights

Certara operates with a gross margin of 61.5%, indicating strong profitability in its software and services.

• The company's market capitalization is $1.17B, reflecting its position in the biosimulation market.
• Certara's beta of 1.62 suggests higher volatility compared to the overall market.
• The company serves a global customer base, with operations in North America, Europe, and Asia-Pacific.
• Certara's solutions are used across the entire drug development lifecycle, from preclinical research to market access.

Who Are CERT's Competitors?

CERT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CERT's Key Strengths?

Comprehensive suite of biosimulation software and services

• Strong scientific expertise
• Global presence
• Established relationships with key customers

What Are CERT's Weaknesses?

Relatively small market capitalization

• Negative profit margin
• High beta indicating volatility
• Dependence on the pharmaceutical industry

What Could Drive CERT Stock Higher?

Increasing adoption of biosimulation in regulatory submissions by the FDA and other agencies.

• Expansion of biosimulation applications in personalized medicine and clinical trial optimization.
• Potential strategic partnerships with major pharmaceutical companies to integrate Certara's solutions.
• Geographic expansion into emerging markets with growing pharmaceutical industries.

What Are the Key Risks for CERT?

Negative return on equity (-1.4%) — the business is not currently generating profit on shareholder capital.

• Increased competition from other biosimulation software and service providers.
• Economic downturn affecting pharmaceutical R&D spending and demand for Certara's solutions.
• Changes in regulatory requirements impacting the adoption of biosimulation.
• Complexity of integrating biosimulation into existing drug development workflows.

What Are the Growth Opportunities for CERT?

• Expansion into Personalized Medicine: Certara can leverage its biosimulation capabilities to support the development of personalized medicine approaches. By integrating patient-specific data into its models, Certara can help clinicians optimize treatment decisions and improve patient outcomes. The personalized medicine market is projected to reach $2.4 billion by 2028, presenting a significant growth opportunity for Certara. Timeline: Ongoing.
• Increased Adoption of Biosimulation in Regulatory Submissions: Regulatory agencies are increasingly recognizing the value of biosimulation in drug development. Certara can capitalize on this trend by expanding its regulatory consulting services and developing software tools that facilitate the use of biosimulation in regulatory submissions. This opportunity is driven by the FDA's growing acceptance of model-informed drug development (MIDD). Timeline: Ongoing.
• Strategic Partnerships with Pharmaceutical Companies: Certara can form strategic partnerships with pharmaceutical companies to integrate its biosimulation solutions into their drug development workflows. These partnerships can provide Certara with access to valuable data and expertise, as well as a recurring revenue stream. The market for pharmaceutical partnerships is continuously evolving as companies seek innovative solutions. Timeline: Ongoing.
• Geographic Expansion into Emerging Markets: Certara can expand its presence in emerging markets, such as China and India, where the pharmaceutical industry is growing rapidly. These markets offer significant growth potential for Certara's software and services. The pharmaceutical market in China is projected to reach $471.6 billion by 2028. Timeline: 2027-2030.
• Development of New Biosimulation Applications: Certara can invest in the development of new biosimulation applications, such as those focused on predicting drug-drug interactions or optimizing clinical trial design. These new applications can expand Certara's addressable market and strengthen its competitive position. The market for clinical trial optimization is expected to grow as companies seek to reduce the cost and time associated with clinical trials. Timeline: 2027-2030.

What Are CERT's Competitive Advantages?

• Proprietary biosimulation software platforms.
• Deep scientific expertise in drug development.
• Long-standing relationships with key customers.
• Strong brand reputation in the biosimulation market.

What Does CERT Do?

Certara, Inc., founded in 2008 and headquartered in Princeton, New Jersey, is a global leader in biosimulation, providing software and technology-enabled services to improve drug development and patient outcomes. The company's mission is to accelerate medicines to patients by using biosimulation to transform traditional drug discovery and development processes. Certara's offerings span the entire drug development lifecycle, from early research and preclinical studies to clinical trials, regulatory submissions, and market access. Certara's core business revolves around its biosimulation software, which includes mechanistic and empirical modeling platforms, data standardization tools, and scientific informatics solutions. These software products enable researchers to simulate drug behavior in the human body, predict clinical outcomes, and optimize dosing regimens. In addition to its software, Certara provides technology-enabled services, such as mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. These services help clients navigate the complexities of drug development and regulatory approval. Certara serves a diverse customer base, including biopharmaceutical companies, academic institutions, and government agencies. The company has a global presence, with operations in North America, Europe, and Asia-Pacific. Certara's solutions are used to develop a wide range of therapies, including small molecules, biologics, and gene therapies. By leveraging biosimulation, Certara helps its clients reduce development costs, accelerate timelines, and improve the probability of success for new medicines.

What Products and Services Does CERT Offer?

• Provides biosimulation software for drug discovery and development.
• Offers technology-enabled services to guide drugs through regulatory submission.
• Develops mechanistic biosimulation platforms.
• Creates empirical PK/PD biosimulation platforms.
• Offers data standardization and compliance software.
• Provides scientific informatics platforms.
• Offers clinical outcomes databases for biosimulation.

How Does CERT Make Money?

• Generates revenue through software subscriptions.
• Provides technology-enabled services to biopharmaceutical companies.
• Offers consulting services related to drug development and regulatory strategy.

What Industry Does CERT Operate In?

Certara operates within the healthcare information services industry, which is experiencing growth driven by the increasing adoption of digital technologies in healthcare and the rising demand for data-driven insights. The biosimulation market, in particular, is expected to grow significantly as pharmaceutical companies seek to improve the efficiency and success rates of drug development. Certara competes with other biosimulation software and service providers, as well as with internal modeling teams within pharmaceutical companies. The company differentiates itself through its comprehensive suite of software and services, its deep scientific expertise, and its global reach.

Who Are CERT's Key Customers?

• Biopharmaceutical companies
• Academic institutions
• Government agencies

Company Profile

Certara, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Radnor, US. The company is led by CEO Jon Resnick. CERT has traded publicly since 2020.

Return on equity for Certara, Inc. stands at -1.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 8.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.5%, the inverse of the P/E and a quick read on earnings relative to price.

CERT Valuation & Market Position

With a $1.17B market cap, Certara, Inc. sits in the small-cap segment of the market. Analyst price targets span from $7.50 to $8.00, with a consensus of $7.75. At the current price of $7.54, that implies approximately 3% upside potential. Relative to its peer group, CERT's quantitative score of 37/100 is below the peer average of 63/100.

Quarterly Financial Performance: Certara, Inc.

Revenue for Certara, Inc. came in at $93.3M during Q2 FY2026, a 12.8% contraction versus the preceding quarter. The company recorded a net loss of $55.3M, with diluted EPS of $-0.36. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CERT averaged $-0.11 in diluted EPS.

Certara, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.98 places it in the grey zone, a middle ground that warrants monitoring.

Certara, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.0% below estimates on average.

Over the past six months, Certara, Inc. insiders filed 27 SEC Form 4 transactions — 12 sales and 15 purchases. On net that is roughly 215K shares acquired (about $83K) — insiders putting money in tends to read as conviction.

CERT Financials

CERT Latest News

CERT Analyst Consensus

CERT MoonshotScore

CERT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources